Ultragenyx Pharmaceutical (RARE) Current Leases (2019 - 2025)

Ultragenyx Pharmaceutical (RARE) has 7 years of Current Leases data on file, last reported at $12.0 million in Q4 2025.

• On a quarterly basis, Current Leases rose 20.0% year-over-year to $12.0 million in Q4 2025; TTM through Dec 2025 was $12.0 million, a 20.0% increase from a year earlier, with the FY2025 full-year figure at $12.0 million, up 20.0% from the prior year.
• Current Leases for Q4 2025 stood at $12.0 million, down from $12.1 million in the prior quarter.
• Over the last five years, Current Leases for RARE reached as high as $12.8 million in Q1 2024 and fell as low as $9.4 million in Q1 2021.
• Historically, Current Leases has averaged $11.3 million across 5 years, with a median of $11.5 million in 2022.
• Across the five-year window, Current Leases surged 37.42% in 2021 and slipped 20.6% in 2024, its largest moves.
• Year by year, Current Leases stood at $11.1 million in 2021, then rose by 6.44% to $11.8 million in 2022, then gained by 6.93% to $12.6 million in 2023, then declined by 20.6% to $10.0 million in 2024, then advanced by 20.0% to $12.0 million in 2025.
• Per Business Quant data, the three most recent Current Leases figures were $12.0 million in Q4 2025, $12.1 million in Q3 2025, and $11.8 million in Q2 2025.